Roche to shed 100 jobs in diabetes Dx revamp

Despite Roche's ($RHHBY) continued diagnostics growth, the company has struggled to turn its diabetes unit around, and now it plans to slash 100 jobs and restructure the operation. Report

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.